Elastin turnover in malignant solid tumors

Connective Tissue Research

Volumn 54, Issue 4-5, 2013, Pages 314-319

  Starcher, Barry ^a   Sauter, Edward ^a   Ho, Coty ^b  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b ST JOHN MEDICAL CENTER   (United States)

Author keywords

Cancer; Chemotherapy; Desmosine; Elastin

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CREATININE; DESMOSINE; ELASTIN; TUMOR MARKER;

AGED; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; PANCREAS CANCER; PROSTATE CANCER; SOLID TUMOR; TISSUE SECTION; TURNOVER TIME; URINALYSIS; URINE LEVEL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CREATININE; DESMOSINE; ELASTIN; HUMANS; MIDDLE AGED; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884219384     PISSN: 03008207     EISSN: 16078438     Source Type: Journal    
DOI: 10.3109/03008207.2013.820723     Document Type: Article

References (53)

1. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci 2010;123: 4195-200.
2. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196: 395-406.
3. Otrlanto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012;3: 203-19.
4. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007;8: 221-33.
5. Aitken KJ, Bägli DJ. The bladder extracellular matrix. Part I: architecture, development and disease. Nat Rev Urol 2009;6: 596-611.
6. Reinke JM, Sorg H. Wound repair and regeneration. Eur Surg Res 2012;49: 35-43.
7. Meng X, Zhong J, Liu S, Murray M, Gonzalez-Angulo AM. A new hypothesis for the cancer mechanism. Cancer Metastasis Rev 2012; 31: 247-68.
8. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. Nat Rev Cancer 2009;9: 108-22.
9. Levental KR, Yu H, Kass L, Lakins NJ, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Glasser DL, Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009;139: 891-906.
10. Ronnov-Jessen L, Petersen OW, Bissell MJ. Cellular changes involved in conversion of normal to malignant breast: importance of the stromal reaction. Physiol Rev 1996;76: 69-125.
11. Giatromanolaki A, Sivridis E, Koukourakis MI. The pathology of tumor stromatogenesis. Cancer Biol Ther 2007;6: 639-47.
12. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012;196: 395-406.
13. Otrlanto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr 2012;3: 203-19.
14. Mantzaris N, Webb S, Othmer HG. Mathematical modeling of tumor-induced angiogenesis. J Math Biol 2004;49: 111-87.
15. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ Res 2005;97: 1093-107.
16. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8: 604-17.
17. Kajita M, Itoh Y, Chiba T, Mori H, Okada A, Kinoh H, Clhiba T, Mori H, Okada A, Kinoh H, Seiki M. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol 2001;153: 893-904.
18. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2: 737-44.
19. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58: 1048-51.
20. Kumar S, Weaver VM. Mechanics, malignancy, and metastasis: the force journey of a tumor cell. Cancer Metastasis Rev 2009;28: 113-27.
21. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010;46: 1181-8.
22. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Seminar Cancer Biol 2010;20: 161-8.
23. Starcher B, Conrad M. A role for neutrophil elastase in the progression of solar elastosis. Connect Tissue Res 1995;31: 133-40.
24. Starcher BC. Determination of the elastin content of tissues by measuring desmosine and isodesmosine. Anal Biochem 1977;79: 11-15.
25. Yu SY, Janoff A, Harel S, Ayvazian VH. Urinary excretion of desmosine in patients with severe burns. Metabolism 1981;30: 497-501.
26. Stone PJ, Franzblau C. Increase in urinary desmosine and pyridinoline during postpartum involution of the uterus in humans. Proc Soc Exp Biol Med 1995;210: 39-42.
27. Memtsoudis SG, Starcher B, Ma Y, Buschiazzo V, Urban MK, Girardi FP. The utility of urine desmosine as a marker of lung injury in spine surgery. HSS J. 2010;6: 160-3.
28. Memtsoudis SG, Valle AG, Jules-Elysse K, Poultsides L, Reid S, Starcher B, Ma Y, Sculco TP. Perioperative inflammatory response in total knee arthroplasty patients: impact of limb preconditioning. Reg Anesth Pain Med 2010;35: 412-16.
29. Bruce MC, Poncz L, Klinger JD, Stern RC, Tomashefski Jr JF, Dearborn DG. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis 1985;132: 529-35.
30. Stone PJ, Konstan MW, Berger M, Dorkin HL, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of patients with cystic fibrosis. Am J Respir Crit Care Med 1995;152: 157-62.
31. Laguna TA, Wagner BD, Starcher B, Luckey Tarro HK, Mann SA, Sagel SD, Accurso FJ. Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation. Pediatr Pulmonol 2012;47: 856-63.
32. Bruce MC, Wedig KE, Jentoft N, Martin RJ, Cheng PW, Boat TF, Fanaroff AA. Altered urinary excretion of elastin cross-links in premature infants who develop bronchopulmonary dysplasia. Am Rev Respir Dis 1985;131: 568-72.
33. Pelham F, Wewers M, Crystal R, Buist AS, Janoff A. Urinary excretion of desmosine (elastin cross-links) in subjects with PiZZ alpha-1-antitrypsin deficiency, a phenotype associated with hereditary predisposition to pulmonary emphysema. Am Rev Respir Dis 1985;132: 821-3.
34. Gottlieb DJ, Luisetti M, Stone PJ, Allegra L, Cantey-Kiser JM, Grassi C, Snider GL. Short-term supplementation therapy does not affect elastin degradation in severe alpha(1)-antitrypsin deficiency. Am J Respir Crit Care Med 2000;162: 2069-72.
35. Osakabe T, Usami E, Sato A, Sasaki S, Watanabe T, Seyama Y. Characteristic change of urinary elastin peptides and desmosine in the aortic aneurysm. Biol Pharm Bull 1999;22: 854-7.
36. Afdhal NH, Keaveny AP, Cohen SB, Nunes DP, Maldonado N, O'Brien M, Stone PJ. Urinary assays for desmosine and hydroxylysylpyridinoline in the detection of cirrhosis. J Hepatol 1997;27: 993-1002.
37. Stone PJ, Korn JH, North H, Lally EV, Miller LC, Tucker LB, Strongwater S, Snider GL, Franzblau C. Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 1995;38: 517-24.
38. Annovazzi L, Viglio S, Gheduzzi D, Pasquali-Ronchetti I, Zanone C, Cetta G, Iadarola P. High levels of desmosines in urine and plasma of patients with pseudoxanthoma elasticum. Eur J Clin Invest 2004;34: 156-64.
39. Starcher B, Green M, Scott M. Measurement of urinary desmosine as an indicator of acute pulmonary disease. Respiration 1995;62: 252-7.
40. McClintock DE, Starcher B, Eisner MD, Thompson BT, Hayden DL, Church GD, Matthay MA. Higher urine desmosine levels are associated with mortality in patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol 2006;291:L566-71.
41. Stone PJ, Gottlieb DJ, O'Connor GT, Ciccolella DE, Breuer R, Bryan-RhadfiJ, Shaw HA, Franzblau C, Snider GL. Elastin and collagen degradation products in urine of smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995;151: 952-9.
42. Ma S, Lin YY, Tartell L, Turino GM. The effect of tiotropium therapy on markers of elastin degradation in COPD. Respir Res 2009;10: 12-19.
43. Luisetti M, Ma S, Iadarola P, Stone PJ, Viglio S, Casado B, Lin YY, Snider GM, Turino GM. Desmosine as a biomarker of elastin degradation in COPD: current status and future directions. Eur Respir J. 2008;32: 1146-7.
44. Huang JT, Chaudhuri R, Albarbarawi O, Barton A, Grierson C, Rauchhaus P, Weir CJ, Messow M, Stevens N, McSharry C, Feuerstein G, Mukhopadhyay S, Brady J, Palmer CN, Miller D, Thomson NC. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 2012;67: 502-8.
45. Sage EH, Gray WR. Evolution of elastin structure. Adv Exp Med Biol 1977;79: 291-312.
46. Starcher BC, Goldstein RA. Studies on the absorption of desmosine and isodesmosine. J Lab Clin Med 1979;94: 848-52.
47. Stone PJ, Lucey EC, Snider GL, Franzblau C. Effect of diet on urinary excretion of desmosine and hydroxylysyl pyridinoline. Am J Respir Crit Care Med 1994;149: 174-7.
48. Goldstein RA, Starcher BC. Urinary excretion of elastin peptides containing desmosine after intratracheal injection of elastase in hamsters. J Clin Invest 1978;61: 1286-90.
49. Starcher B, Peterson B. The kinetics of elastolysis: elastin catabolism during experimentally induced fibrosis. Exp Lung Res 1999;25: 407-24.
50. Dubick MA, Rucker RB, Cross CE, Last JA. Elastin metabolism in rodent lung. Biochim Biophys Acta 1981;672: 303-6.
51. Shapiro SD, Endicott SK, Province MA, Pierce JA, Campbell EJ. Marked longevity of human lung parenchymal elastic fibers deduced from prevalence of D-aspartate and nuclear weaponsrelated radiocarbon. J Clin Invest 1991;87: 1828-34.
52. Ritz-Timme S, Laumeier I, Collins MJ. Aspartic acid racemization: evidence for marked longevity of elastin in human skin. Br J Dermatol 2003;149: 951-9.
53. Boutin M, Ahmad I, Jauhiainen M, Lachapelle N, Rondeau C, Roy J, and Thibault P. NanoLC-MS/MS analyses of urinary desmosine, hydroxylysylpyridinoline and lysylpyridinoline as biomarkers for chronic graft-versus-host disease. Anal Chem 2009;81: 9454-61.